These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 16707591)

  • 1. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses.
    Hirano N; Butler MO; Xia Z; Berezovskaya A; Murray AP; Ansén S; Nadler LM
    Clin Cancer Res; 2006 May; 12(10):2967-75. PubMed ID: 16707591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells.
    Bellone M; Iezzi G; Manfredi AA; Protti MP; Dellabona P; Casorati G; Rugarli C
    Eur J Immunol; 1994 Nov; 24(11):2691-8. PubMed ID: 7525300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
    Dupont J; Latouche JB; Ma C; Sadelain M
    Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.
    Chakraborty NG; Chattopadhyay S; Mehrotra S; Chhabra A; Mukherji B
    Hum Immunol; 2004 Aug; 65(8):794-802. PubMed ID: 15336780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
    Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ
    Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
    Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
    Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells.
    Stronen E; Abrahamsen IW; Gaudernack G; Wälchli S; Munthe E; Buus S; Johansen FE; Lund-Johansen F; Olweus J
    Scand J Immunol; 2009 Apr; 69(4):319-28. PubMed ID: 19284496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines.
    Nair SK; Boczkowski D; Snyder D; Gilboa E
    Eur J Immunol; 1997 Mar; 27(3):589-97. PubMed ID: 9079797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen presentation of a modified tumor-derived peptide by tumor infiltrating lymphocytes.
    Dionne SO; Smith MH; Marincola FM; Lake DF
    Cell Immunol; 2001 Dec; 214(2):139-44. PubMed ID: 12088412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
    Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
    Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses.
    Chapatte L; Ayyoub M; Morel S; Peitrequin AL; Lévy N; Servis C; Van den Eynde BJ; Valmori D; Lévy F
    Cancer Res; 2006 May; 66(10):5461-8. PubMed ID: 16707475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
    Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
    Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allo-restricted CTLs generated by coculturing of PBLs and autologous monocytes loaded with allogeneic peptide/HLA/IgG1-Fc fusion protein.
    Weng X; Lu S; Zhong M; Liang Z; Shen G; Chen J; Wu X
    J Leukoc Biol; 2009 Mar; 85(3):574-81. PubMed ID: 19112092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of tumor antigen-specific cytotoxic T cell responses in naïve mice by latex microspheres-based artificial antigen-presenting cell constructs.
    Shen C; Zhang J; Xia L; Meng F; Xie W
    Cell Immunol; 2007 May; 247(1):28-35. PubMed ID: 17720150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro.
    Schumacher R; Amacker M; Neuhaus D; Rosenthal R; Groeper C; Heberer M; Spagnoli GC; Zurbriggen R; Adamina M
    Vaccine; 2005 Dec; 23(48-49):5572-82. PubMed ID: 16165256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Particulate naturally processed peptides prime a cytotoxic response against human melanoma in vitro.
    Protti MP; Imro MA; Manfredi AA; Consogno G; Heltai S; Arcelloni C; Bellone M; Dellabona P; Casorati G; Rugarli C
    Cancer Res; 1996 Mar; 56(6):1210-3. PubMed ID: 8640799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
    Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
    Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.
    Oelke M; Maus MV; Didiano D; June CH; Mackensen A; Schneck JP
    Nat Med; 2003 May; 9(5):619-24. PubMed ID: 12704385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
    Ishizaki H; Tsunoda T; Wada S; Yamauchi M; Shibuya M; Tahara H
    Clin Cancer Res; 2006 Oct; 12(19):5841-9. PubMed ID: 17020992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.